Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress
Results from preclinical osteoarthritis (OA) models demonstrate relief of pain, functional improvement and suggest disease-modifying efficacy following a single intra-articular injection BURLINGTON, Mass., April 29, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML
Toggle Summary Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World Congress
Average time to second administration was more than 16 weeks 74% of patients received second administration of ZILRETTA between Weeks 16 and 24 Results indicate robust treatment response in a "real-world" patient group that includes those with Kellgren-Lawrence Grade 4 osteoarthritis, the most
View HTML
Toggle Summary Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018
Post-hoc analysis indicated ZILRETTA provided significant improvements in pain and function in patients with unilateral knee osteoarthritis Abstract receives silver ribbon designation BURLINGTON, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery
BURLINGTON, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the key results from the previously completed pivotal Phase 3 study evaluating ZILRETTA (triamcinolone acetonide extended-release injectable suspension) have been published in the
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 12,300 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference
BURLINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at Needham &
View HTML
Toggle Summary Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Early launch activities for ZILRETTA ® progressing well (strong clinical interest from prescribers; broad coverage from payers; encouraging feedback from patients)    Company booked net ZILRETTA sales of approximately $355K in Q4 Encouraging initial results from repeat administration trial of
View HTML
Toggle Summary Flexion Therapeutics to Present at the Cowen 38th Annual Health Care Conference
BURLINGTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will be presenting at the Cowen 38th Annual Health Care Conference in Boston, Massachusetts. Michael Clayman, M.D., President and Chief Executive Officer, is scheduled to present at 10:40 a.m.
View HTML
Toggle Summary Flexion Therapeutics Presents Clinical Data at AAOS 2018 Annual Meeting and the American Pain Society Annual Scientific Meeting
Post-hoc analysis demonstrates potential of ZILRETTA ®  (triamcinolone acetonide extended-release injectable suspension) to provide effective pain relief regardless of prior intra-articular corticosteroid use Effects of ZILRETTA show improvement on health-related quality of life in patients with
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to two new employees for an aggregate of 4,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
View HTML